The present finding that RAD52 S346X reduces cancer risk in BRCA mutation carriers suggests that RAD52 inhibitors may also be used to reduce breast cancer risk in BRCA1/2 mutation carrier. This evidence concerns the gene BRCA1 and breast carcinoma.